{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:20:54Z","timestamp":1781842854133,"version":"3.54.5"},"reference-count":173,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2017,7,3]]},"DOI":"10.1080\/14737175.2017.1326818","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T09:58:35Z","timestamp":1494496715000},"page":"683-695","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":40,"title":["Emerging treatments for Alzheimer\u2019s disease for non-amyloid and non-tau targets"],"prefix":"10.1080","volume":"17","author":[{"given":"Ayesha","family":"Khan","sequence":"first","affiliation":[{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Corbett","sequence":"additional","affiliation":[{"name":",","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Ballard","sequence":"additional","affiliation":[{"name":",","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,5,18]]},"reference":[{"key":"e_1_3_2_3_1","unstructured":"Dementia statistics. Available from: http:\/\/www.alz.co.uk\/research\/statistics"},{"key":"e_1_3_2_4_1","unstructured":"World Alzheimer Report 2015. The global impact of dementia an analysis of prevalence incidence cost and trends. Available from: http:\/\/www.alz.co.uk\/research\/WorldAlzheimerReport2015-sheet.pdf."},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12191"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S45143"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.5847"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-385883-2.00008-4"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(91)90609-V"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2460"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1586\/ern.09.24"},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","unstructured":"Khan A Ballard CB. Emerging amyloid and tau targeting treatments for Alzheimer\u2019s disease. 2017. Accepted in Exp. Rev. of Neurother. 2017.","DOI":"10.1080\/14737175.2017.1326819"},{"key":"e_1_3_2_13_1","volume-title":"Caring for a person with dementia","unstructured":"Caring for a person with dementia. drug treatments. Available from:\u00a0https:\/\/www.alz.co.uk\/caring\/drug-treatments."},{"issue":"1","key":"e_1_3_2_14_1","first-page":"CD001747","article-title":"Galantamine for Alzheimer\u2019s disease and mild cognitive impairment","author":"Loy C","year":"2006","unstructured":"Loy C, Schneider L. Galantamine for Alzheimer\u2019s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;1:CD001747.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"e_1_3_2_15_1","first-page":"CD001191","article-title":"Rivastigmine for Alzheimer\u2019s disease","author":"Birks J","year":"2009","unstructured":"Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2009;2:CD001191.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"e_1_3_2_16_1","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer\u2019s disease","author":"Birks J","year":"2006","unstructured":"Birks J. Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006;1:CD005593.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106668"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyu115"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200421060-00004"},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjopharm.2006.10.001","article-title":"Recommendations for best practices in the treatment of Alzheimer\u2019s disease in managed care","volume":"4","author":"Fillit HM","year":"2006","unstructured":"Fillit HM, Doody RS, Binaso K, et al. Recommendations for best practices in the treatment of Alzheimer\u2019s disease in managed care. Am J Geriatr Pharmacother. 2006;4(Suppl A):S9-S24; quiz S25-S28.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"11","key":"e_1_3_2_21_1","first-page":"1269","article-title":"Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials","volume":"167","author":"Wooltorton E","year":"2002","unstructured":"Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. Cmaj. 2002;167(11):1269\u20131270.","journal-title":"Cmaj"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1040539"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.5.596"},{"issue":"1","key":"e_1_3_2_24_1","first-page":"CD003476","article-title":"The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer\u2019s disease","author":"Ballard C","year":"2006","unstructured":"Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006;1:CD003476.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70295-3"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.15.1934"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.2165\/11584290-000000000-00000"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2005.04.007"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1102884"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2008.05.008"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145710000659"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70198-X"},{"key":"e_1_3_2_33_1","unstructured":"Study of Lu AE58054 in patients with mild - moderate Alzheimer\u2019s disease treated with donepezil (STARSHINE). Available from: https:\/\/www.clinicaltrials.gov\/show\/NCT01955161."},{"key":"e_1_3_2_34_1","unstructured":"Lu AE58054 in patients with mild-moderate Alzheimer\u2019s disease treated with donepezil (STARBEAM). Available from: https:\/\/www.clinicaltrials.gov\/show\/NCT02006641."},{"key":"e_1_3_2_35_1","unstructured":"Lu AE58054 in patients with mild to moderate Alzheimer\u2019s disease treated with an acetylcholinesterase inhibitor (STARBRIGHT). Available from: https:\/\/www.clinicaltrials.gov\/show\/NCT02006654."},{"key":"e_1_3_2_36_1","unstructured":"Long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer\u2019s disease (STAR Extension). Available from: https:\/\/www.clinicaltrials.gov\/show\/NCT02079246."},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2013.01.035"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.06.034"},{"key":"e_1_3_2_39_1","unstructured":"A study of SB-742457 added to donepezil for the treatment of mild-to-moderate Alzheimer\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/show\/NCT00710684."},{"key":"e_1_3_2_40_1","unstructured":"Study of SB-742457 or donepezil versus placebo in subjects with mild-to-moderate Alzheimer\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/show\/NCT00708552."},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720510791383831"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2011.01.004"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-142421"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-009-9269-5"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.3109\/13506120308995249"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720509787602915"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2006.01.020"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720507783018163"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1997.00550160091022"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S55104"},{"key":"e_1_3_2_51_1","unstructured":"Rare but severe side effects sideline some phase 3 encenicline trials. Available from: http:\/\/www.alzforum.org\/news\/research-news\/rare-severe-side-effects-sideline-some-phase-3-encenicline-trials."},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2015.03.029"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.226712"},{"key":"e_1_3_2_54_1","unstructured":"Efficacy and Safety of MK-7622 as adjunct therapy in participants with Alzheimer\u2019s disease (MK-7622-012). Available from: https:\/\/www.clinicaltrials.gov\/show\/NCT01852110."},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110379286"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.70"},{"key":"e_1_3_2_57_1","unstructured":"Phase 2a dose finding PK\/PD and 12 month exploratory efficacy study of ANAVEX2-73 in patients with Alzheimer\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/show\/NCT02244541."},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1092520"},{"key":"e_1_3_2_59_1","unstructured":"A study of two fixed-doses of brexpiprazole in the treatment of subjects with agitation associated with dementia of the Alzheimer\u2019s type. Available from: https:\/\/www.clinicaltrials.gov\/show\/NCT01862640."},{"key":"e_1_3_2_60_1","unstructured":"Safety and tolerability study of flexible dosing of brexpiprazole in the treatment of subjects with agitation associated with dementia of the Alzheimer\u2019s type. Available from: https:\/\/www.clinicaltrials.gov\/show\/NCT01922258."},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(03)01308-6"},{"key":"e_1_3_2_62_1","unstructured":"Orion Corporation presented promising Phase II data for new Alzheimer\u2019s disease drug at AAN annual meeting. Available from: http:\/\/www.orion.fi\/en\/Orion-group\/media\/press-releases\/2013\/orion-corporation-presented-promising-phase-ii-data-for-new-alzheimers-disease-drug-at-aan-annual-meeting\/."},{"key":"e_1_3_2_63_1","unstructured":"Efficacy of ORM-12741 on agitation\/aggression symptoms in Alzheimer\u2019s Disease (Nebula). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02471196."},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.93"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10214"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000260240.46070.7c"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610212002141"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp060066m"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-140093"},{"key":"e_1_3_2_70_1","unstructured":"Trial of dronabinol adjunctive treatment of agitation in Alzheimer\u2019s disease (AD) (THC-AD). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02792257."},{"key":"e_1_3_2_71_1","unstructured":"Safety and efficacy of nabilone in Alzheimer\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02351882."},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph6101304"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3869"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.10611"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2011.11.005"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2010.08.028"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0529-11.2011"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.22565"},{"key":"e_1_3_2_79_1","unstructured":"Evaluating Liraglutide in Alzheimer\u2019s disease (ELAD). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01843075."},{"key":"e_1_3_2_80_1","volume-title":"A pilot clinical trial of exendin-4 in Alzheimer\u2019s disease","unstructured":"A pilot clinical trial of exendin-4 in Alzheimer\u2019s disease. Available from:\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01255163."},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2011.07.001"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001442"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1089\/rej.2009.0944"},{"key":"e_1_3_2_84_1","unstructured":"Reducing pathology in Alzheimer\u2019s disease through angiotensin targeting. Available from: http:\/\/www.isrctn.com\/ISRCTN93682878."},{"key":"e_1_3_2_85_1","unstructured":"Telmisartan vs. perindopril in hypertensive mild-moderate Alzheimer\u2019s disease patients (SARTAN-AD). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02085265."},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(00)02380-2"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/glia.20051"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4371-06.2007"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1159\/000285514"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-100204"},{"key":"e_1_3_2_91_1","unstructured":"Minocycline in Alzheimer\u2019s disease efficacy (MADE) trial Available from: http:\/\/public.ukcrn.org.uk\/search\/StudyDetail.aspx?StudyID=14866."},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3178"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24394"},{"key":"e_1_3_2_94_1","unstructured":"Safety and tolerability of AZD0530 (Saracatinib) in Alzheimer\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01864655."},{"key":"e_1_3_2_95_1","unstructured":"A phase ii a multi-center study of 18F-FDG PET safety and tolerability of AZD0530 in mild Alzheimer\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02167256."},{"key":"e_1_3_2_96_1","unstructured":"Investigating the potential of a common drug to treat a cause of vascular dementia and contributor to Alzheimer\u2019s disease. Available from: https:\/\/www.alzheimers.org.uk\/site\/scripts\/documents_info.php?documentID=2845."},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml2001455"},{"key":"e_1_3_2_98_1","unstructured":"A PET study of the effects of p38 MAP kinase inhibitor VX-745 on amyloid plaque load in Alzheimer\u2019s disease (AD). Available from: https:\/\/www.clinicaltrials.gov\/show\/NCT02423122."},{"key":"e_1_3_2_99_1","unstructured":"Clinical pharmacology of p38 MAP kinase inhibitor VX-745 in mild cognitive impairment due to Alzheimer\u2019s disease (AD) or mild AD. Available from: https:\/\/www.clinicaltrials.gov\/show\/NCT02423200."},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70178-3"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.10.038"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-386467-3.00010-8"},{"key":"e_1_3_2_103_1","unstructured":"A 3 year study to evaluate the safety and efficacy of low dose ladostigil in patients with mild cognitive impairment (MCI). Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01429623."},{"key":"e_1_3_2_104_1","unstructured":"Safety and efficacy study of ladostigil in mild to moderate probable Alzheimer\u2019s disease. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01354691."},{"key":"e_1_3_2_105_1","unstructured":"Available from: http:\/\/www.avphar.com\/avraham-pharmaceuticals-announces-successful-second-interim-results-in-phase-2b-study-of-ladostigil-for-the-treatment-of-mild-cognitive-impairment\/."},{"key":"e_1_3_2_106_1","unstructured":"A study of PF-04447943 compared to placebo in subjects with mild to moderate Alzheimer\u2019s disease. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00930059."},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.2174\/1567205011666140505100858"},{"key":"e_1_3_2_108_1","unstructured":"Available from: www.news-medical.net\/news\/20090923\/ C.-t.t.s.t.p.o.A.s.d. and C.-.-t.-t.-s.-t.-p.-o.-. Alzheimers-disease.aspx."},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1080\/10611860903112842"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0901402106"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14142"},{"key":"e_1_3_2_112_1","unstructured":"The safety and the efficacy evaluation of NEUROSTEM\u00ae-AD in patients with Alzheimer\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01297218."},{"key":"e_1_3_2_113_1","unstructured":"Safety and exploratory efficacy study of NEUROSTEM\u00ae versus placebo in patients with Alzheimer\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02054208."},{"key":"e_1_3_2_114_1","unstructured":"Safety and efficiency of umbilical cord-derived mesenchymal stem cells(UC-MSC) in patients with Alzheimer\u2019s Disease (SEMAD). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01547689."},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2010.01.013"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neures.2006.06.010"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1510"},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1857"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.10.1402"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2009-1033"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.1177\/1533317508325094"},{"key":"e_1_3_2_122_1","unstructured":"A multicenter trial of rofecoxib and naproxen in Alzheimer\u2019s disease (NSAID study). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00004845."},{"key":"e_1_3_2_123_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1866"},{"key":"e_1_3_2_124_1","first-page":"CD006378","article-title":"Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer\u2019s disease","volume":"2","author":"Jaturapatporn D","year":"2012","unstructured":"Jaturapatporn D, Isaac MG, McCleery J, et al. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2012;2:CD006378.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.8.1609"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001475"},{"key":"e_1_3_2_127_1","unstructured":"Study evaluating safety tolerability and PK of multiple ascending doses of GC021109 in subjects with mild to moderate Alzheimer\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02386306."},{"issue":"7","key":"e_1_3_2_128_1","first-page":"672","article-title":"The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer\u2019s disease","volume":"10","author":"Schmidt AM","year":"2009","unstructured":"Schmidt AM, Sahagan B, Nelson RB, et al. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer\u2019s disease. Curr Opin Investig Drugs. 2009;10(7):672\u2013680.","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_2_129_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2008.96"},{"key":"e_1_3_2_130_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4878-07.2008"},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e318204b550"},{"key":"e_1_3_2_132_1","unstructured":"A phase 2 study evaluating the efficacy and safety of PF 04494700 in mild to moderate Alzheimer\u2019s disease. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00566397."},{"key":"e_1_3_2_133_1","unstructured":"A phase 2 study evaluating the efficacy and safety of PF 04494700 In mild to moderate Alzheimer\u2019s disease. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00566397."},{"key":"e_1_3_2_134_1","unstructured":"Evaluation of the efficacy and safety of Azeliragon (TTP488) in patients with mild Alzheimer\u2019s disease (STEADFAST). Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02080364."},{"key":"e_1_3_2_135_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.13.111"},{"key":"e_1_3_2_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2008.07.005"},{"key":"e_1_3_2_137_1","doi-asserted-by":"publisher","DOI":"10.3109\/01677063.2011.630494"},{"key":"e_1_3_2_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2006.01.008"},{"key":"e_1_3_2_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.12.021"},{"key":"e_1_3_2_140_1","unstructured":"BI 409306 in patients with cognitive impairment due to Alzheimer\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02337907."},{"key":"e_1_3_2_141_1","unstructured":"Alzheimer disease proof of concept study with BI 409306 versus placebo. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02240693."},{"key":"e_1_3_2_142_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.33.20967"},{"key":"e_1_3_2_143_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-091471"},{"key":"e_1_3_2_144_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddp331"},{"issue":"1","key":"e_1_3_2_145_1","article-title":"Granulocyte macrophage colony stimulating factor treatment is associated with improved cognition in cancer patients","volume":"1","author":"Jim HS","year":"2012","unstructured":"Jim HS, Boyd TD, Booth-Jones M, et al. Granulocyte macrophage colony stimulating factor treatment is associated with improved cognition in cancer patients. Brain Disord Ther. 2012;1(1):1000101.","journal-title":"Brain Disord Ther"},{"key":"e_1_3_2_146_1","unstructured":"Study of the safety & efficacy of Leukine\u00ae in the treatment of Alzheimer\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01409915."},{"key":"e_1_3_2_147_1","unstructured":"Study to evaluate the safety tolerability and pharmacokinetics of ABT-957 in subjects with mild-to-moderate Alzheimer\u2019s disease on stable doses of acetylcholinesterase inhibitors. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02220738."},{"key":"e_1_3_2_148_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024293"},{"key":"e_1_3_2_149_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1001422107"},{"key":"e_1_3_2_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2015.01.019"},{"key":"e_1_3_2_151_1","unstructured":"Allopregnanolone for mild cognitive impairment due to Alzheimer\u2019s disease or mild AD. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02221622."},{"key":"e_1_3_2_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2007.12.005"},{"key":"e_1_3_2_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2006.12.008"},{"key":"e_1_3_2_154_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903563106"},{"key":"e_1_3_2_155_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2004.02438.x"},{"key":"e_1_3_2_156_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61074-0"},{"key":"e_1_3_2_157_1","first-page":"CD009524","article-title":"Latrepirdine for Alzheimer\u2019s disease","volume":"4","author":"Chau S","year":"2015","unstructured":"Chau S, Herrmann N, Ruthirakuhan MT, et al. Latrepirdine for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2015;4:CD009524.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_158_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.233"},{"key":"e_1_3_2_159_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000265401.62434.36"},{"key":"e_1_3_2_160_1","unstructured":"(SNIFF). T.S.o.N.I.i.t.F.A.F. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01767909."},{"key":"e_1_3_2_161_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2004.03563.x"},{"key":"e_1_3_2_162_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150450"},{"key":"e_1_3_2_163_1","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e3181d5792a"},{"key":"e_1_3_2_164_1","doi-asserted-by":"publisher","DOI":"10.3928\/00989134-20090301-10"},{"key":"e_1_3_2_165_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.183.3.248"},{"key":"e_1_3_2_166_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09042"},{"key":"e_1_3_2_167_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1015950108"},{"key":"e_1_3_2_168_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.307"},{"key":"e_1_3_2_169_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.9.1027"},{"key":"e_1_3_2_170_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.wad.0000184005.22611.cc"},{"key":"e_1_3_2_171_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.003"},{"key":"e_1_3_2_172_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70291-0"},{"key":"e_1_3_2_173_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202753"},{"key":"e_1_3_2_174_1","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt59"},{"key":"e_1_3_2_175_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2011.06.005"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2017.1326818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T18:00:15Z","timestamp":1770919215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2017.1326818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,18]]},"references-count":173,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7,3]]}},"alternative-id":["10.1080\/14737175.2017.1326818"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2017.1326818","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}